TriNetX LATAM Collaborative Network, an EHR Data Source in Latin America.

Authors

Vinicius Pinho, Lucas Tramujas, Willian Soares, Matvey B Palchuk, K Arnold Chan

Published in

Pharmacoepidemiology and drug safety. Volume 35. Issue 10. Pages e70459.

Abstract

In 2014, TriNetX launched a U.S.-based federated network of health system electronic health records (EHR) that is now used in academic and industry-sponsored studies and includes more than 250 health care organizations (HCOs) globally. The network expanded to Latin America in 2018, where currently there are over 40 HCO partners in Brazil and Colombia. This manuscript describes the TriNetX LATAM Collaborative Network and outlines how it may support observational studies and clinical trials.
We queried the LATAM Collaborative Network to determine patient counts for selected disease conditions. We used diagnosis codes, plus drug prescription and/or biometric measures to estimate the frequency of diabetes, hypertension, heart failure, renal impairment, and chronic obstructive pulmonary disease, and estimated survival among patients with breast cancer and prostate cancer.
Approximately 4.54 million patients had at least one healthcare encounter in the data system in 2025; 58.8% of them were female, and 30% were age 60 or older. About 1 million adult patients had a diagnosis of hypertension, prescription of an angiotensin-converting enzyme inhibitor or angiotensin II antagonist, or systolic blood pressure above 140 mmHg. Among adult patients who had at least one serum estimated glomerular filtration test, 6.7% (43 720 of 655 560) had 2 instances of value < 60 mL/min/{1.73_m²} at least 3 months apart. Among 166 490 women with breast cancer, 5-year survival was 90.7%. Among 116 900 men with prostate cancer, 5-year survival was 91.1%.
TriNetX LATAM Collaborative Network represents an emerging, scalable EHR-based data source to support pharmacoepidemiology studies and clinical trials.

PMID:
42764402
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.